Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting
Tóm tắt
Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation drugs has been questioned. Our goal is to evaluate the effects of smoking cessation drugs on blood pressure and heart rate in patients from a smoking cessation service in a cardiology hospital. We examined the PAF database (Smoking Cessation Assistance Program database) between January 2008 and March 2014. We analyzed data from 900 patients who were compliant with the treatment (50.5 % male, average age 53 ± 17 years). The most frequent clinical diagnoses were coronary artery disease (25.2 %), hypertension (57.2 %), and diabetes (13.4 %). Blood pressure, heart rate, and carbon monoxide (CO) concentration in exhaled air were analyzed at consecutive visits during the first 45 days of treatment (mean visits - 3). Analysis of repeated measures was used for the statistical analysis (p < 0.05). Two hundred seventy one patients used nicotine replacement therapy (NRT) alone, 81 used bupropion alone, 154 used varenicline alone, 283 used NRT plus bupropion and 111 used bupropion plus varenicline. For all smoking cessation drugs, used alone or in combination, no increase occurred in the average value of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Significant reductions in CO concentrations occurred in all smoking cessation drug groups. Smoking cessation drugs used in monotherapy or in combined regimens did not influence systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in this group of patients during the observation period.
Tài liệu tham khảo
Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341–50. doi:10.1056/NEJMsa1211128.
Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2012;379:1269–71. doi:10.1016/S0140-6736(11)60615-6.
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update.Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. 2008.
DaCosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993;14:1709–11.
Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010; 8(1): 8. doi: 10.1186/1617-9625-8-8.
Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129:28–41. doi:10.1161/CIRCULATIONAHA.113.003961.
Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006;119:1080–7. doi:10.1016/j.amjmed.2006.04.024.
Tonstad S. Bupropion SR, for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946–55. doi:10.1016/S0195-668X(03)00003-4.
Eisenberg MJ, Grandi SM, Gervais A, O’Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2013;61:524–32. doi:10.1016/j.jacc.2012.08.1030.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–9. doi:10.1161/CIRCULATIONAHA.109.869008.
Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011;183:1359–66. doi:10.1503/cmaj.110218.
Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344, e2856. doi:10.1136/bmj.e2856.
Issa JS, Abe TO, Moura S, Santos PCJL, Pereira AC. Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res. 2013;15(6):1146–50. doi:10.1093/ntr/nts230.
Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers. A randomized trial. JAMA. 2014;311(2):155–63. doi:10.1001/jama.2013.283185.
Rose JE, Behm FM. Combination varenicline/bupropion treatment in an adaptative smoking cessation paradigm. Am J Psychiatry. 2014;171(11):1199–205. doi:10.1176/appi.ajp.2014.13050595.
Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med. 1989;12:159–82.
Issa JS. A new nicotine dependence score and a new scale assessing patient comfort during smoking cessation treatment. J Bras Pneumol. 2012;38:761–5.
Issa JS, Abe TM, Pereira AC, Megid MC, Shimabukuro CE, Valentin LS, et al. The effect of São Paulo’s smoke-free legislation on carbon monoxide concentration in hospitality venues and their workers. Tob Control. 2011;20:156–62. doi:10.1136/tc.2010.037614.
Najem B, Houssière A, Pathak A, Janssen C, Lemogoum D, Xhaët O, et al. Acute cardiovascular and sympathetic effects of nicotine replacement therapy. Hypertension. 2006;47:1162–7. doi:10.1161/01.HYP.0000219284.47970.34.
Yugar-Toledo JC, Ferreira-Melo SE, Sabha M, Nogueira EA, Coelho OR, Consolin Colombo FM, et al. Blood Pressure circadian rhythm and endothelial function in heavy smokers: acute effects of transdermal nicotine. J Clin Hypertens (Greenwich). 2005;7:721–8.
Sobieraj DM, White WB, Baker WL. Cardiovascular effects of pharmacologic therapies for smoking cessation. J Am Soc Hypertens. 2013;7:61–7. doi:10.1016/j.jash.2012.11.003.
Settle EC, Stahl SM, Batey SR, Andrew Johnston J, Ascher JA. Safety profile of sustained-release bupropion in depression: Results of three clinical trials. Clin Ther. 1999;21:454–63. doi:10.1016/S0149-2918(00)88301-0.
Thase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol. 2008;28:302–7. doi:10.1097/JCP.0b013e318172424e.
Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J. 2000;140 Suppl 4:84–8.
Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512–6.
Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA-EXPRESS. 2006;296:64–71.
Tanus-Santos JE, Carlos J, Toledo Y. Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers. Am J Hypertens. 2001;14:610–4.
Zevin S, Jacob P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998;64:87–95. doi:10.1016/S0009-9236(98)90026-1.